Introduction: Low back pain (LBP), a global disability leader, is often linked to intervertebral disc (IVD) degeneration. Traditional diagnostics like T2-weighted MRI provide qualitative but imprecise evaluations. A novel post-processing MRI technique, Decay Variance (DeVa), has shown promise in differentiating degenerate from healthy discs in animal studies. DeVa quantifies IVD degeneration by analyzing variations in signal intensities within each voxel in a T2* 2D FLASH multi-echo MRI sequence. This study aimed to validate DeVa clinically and explore its correlation with pain severity.
Methods: A cross-sectional study included 77 chronic LBP patients and 8 controls, who underwent T2-weighted and T2* 2D FLASH MRI. DeVa scores (worst and sum of all discs) were recorded, alongside traditional assessments like disc bulge, stenosis, high-intensity zones, and Pfirrmann grade. Pain severity was measured with a numerical rating scale. Statistical analyses included Pearson correlation, -tests, and Gardner-Altman plots to evaluate relationships between DeVa scores, degeneration, and pain.
Results: DeVa scores correlated strongly with Pfirrmann grade ( = 0.692, < 0.001) and were significantly higher in discs with bulge, stenosis, or high-intensity zones ( < 0.001). Moderate correlations were observed between worst DeVa scores ( = 0.296, < 0.01), total DeVa scores ( = 0.323, < 0.005) and pain severity. Patients with chronic LBP without severe degeneration (Pfirrmann ≤ 3 with no stenosis observable on standard MRI) had significantly higher worst (1.38 ± 0.26 vs. 1.10 ± 0.29, < 0.005) and total (5.39 ± 0.75 vs. 4.65 ± 0.61, < 0.0.1) DeVa scores compared to controls.
Discussion: DeVa offers a quantitative, noninvasive approach to assessing IVD degeneration, showing strong correlations with disc health and pain. It demonstrates enhanced sensitivity over traditional MRI, enabling the identification of pain-generating discs and informing personalized treatment strategies for chronic LBP. Further validation in larger populations is needed.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11885163 | PMC |
http://dx.doi.org/10.1002/jsp2.70056 | DOI Listing |
JOR Spine
March 2025
Spine Labs, Department of Orthopedic Surgery, St George and Sutherland Clinical School University of New South Wales Sydney Australia.
Introduction: Low back pain (LBP), a global disability leader, is often linked to intervertebral disc (IVD) degeneration. Traditional diagnostics like T2-weighted MRI provide qualitative but imprecise evaluations. A novel post-processing MRI technique, Decay Variance (DeVa), has shown promise in differentiating degenerate from healthy discs in animal studies.
View Article and Find Full Text PDFRadiology
February 2025
Department of Medical Imaging, St Michael's Hospital, University of Toronto, 30 Bond St, Toronto, ON, Canada M5B 1W8.
Background Although pericardial calcification has been observed on chest CT scans in patients with cystic fibrosis (CF), its prevalence and characteristics have not been elucidated. Purpose To determine the prevalence and characteristics of pericardial calcification, and identify clinical variables associated with it, in adult patients with CF and to compare this prevalence with that in individuals without CF. Materials and Methods This was a retrospective, single-center case-control study including consecutive patients with CF who underwent chest CT between January 2021 and December 2022.
View Article and Find Full Text PDFClin Exp Metastasis
February 2025
Medical Oncology Unit, Macerata Hospital, Macerata, Italy.
Patients with metastatic urothelial carcinoma (mUC) are typically elderly and often have other comorbidities that require the use of concomitant medications. In our study we evaluated the association of concomitant use of antibiotics (ATBs), proton pump inhibitors (PPIs), corticosteroids, statins, metformin and insulin with patient outcomes and we validated the prognostic role of a concomitant drug score in mUC patients treated with enfortumab vedotin (EV) monotherapy. Data from 436 patients enrolled in the ARON-2 retrospective study were analyzed according to the concomitant medications used at baseline.
View Article and Find Full Text PDFWorld Allergy Organ J
December 2024
National Allergy Council, Sydney NSW, 2000, Australia.
Respir Med
January 2025
Ankara University School of Medicine, Department of Chest Disease, Division of Immunology and Allergy, Ankara, Turkey.
Current guidelines recommend adding long-acting muscarinic antagonists (LAMAs) in patients with uncontrolled asthma, despite the use of moderate to high doses of inhaled steroid-long-acting beta agonists (ICS/LABA). This study aims to analyze the factors related to the prescription of add-on LAMA in clinical practice for asthma patients, shedding light on physicians' preferences. This study included adult asthma patients on add-on LAMA and ICS/LABA monitored for at least one year in a national registry comprising 2053 asthmatics.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!